Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.56
TMO's Cash to Debt is ranked higher than
58% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.74 vs. TMO: 0.56 )
TMO' s 10-Year Cash to Debt Range
Min: 0.11   Max: 2.13
Current: 0.56

0.11
2.13
Equity to Asset 0.53
TMO's Equity to Asset is ranked higher than
61% of the 285 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.63 vs. TMO: 0.53 )
TMO' s 10-Year Equity to Asset Range
Min: 0.33   Max: 0.75
Current: 0.53

0.33
0.75
Interest Coverage 6.14
TMO's Interest Coverage is ranked higher than
55% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.61 vs. TMO: 6.14 )
TMO' s 10-Year Interest Coverage Range
Min: 3.02   Max: 21.63
Current: 6.14

3.02
21.63
F-Score: 6
Z-Score: 2.97
M-Score: -2.64
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 12.30
TMO's Operating margin (%) is ranked higher than
80% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.44 vs. TMO: 12.30 )
TMO' s 10-Year Operating margin (%) Range
Min: 1.56   Max: 14.42
Current: 12.3

1.56
14.42
Net-margin (%) 9.73
TMO's Net-margin (%) is ranked higher than
79% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.65 vs. TMO: 9.73 )
TMO' s 10-Year Net-margin (%) Range
Min: -7.07   Max: 16.75
Current: 9.73

-7.07
16.75
ROE (%) 7.55
TMO's ROE (%) is ranked higher than
73% of the 283 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.68 vs. TMO: 7.55 )
TMO' s 10-Year ROE (%) Range
Min: -8.67   Max: 15.26
Current: 7.55

-8.67
15.26
ROA (%) 4.00
TMO's ROA (%) is ranked higher than
73% of the 290 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.24 vs. TMO: 4.00 )
TMO' s 10-Year ROA (%) Range
Min: -3.37   Max: 10.12
Current: 4

-3.37
10.12
ROC (Joel Greenblatt) (%) 43.75
TMO's ROC (Joel Greenblatt) (%) is ranked higher than
89% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.38 vs. TMO: 43.75 )
TMO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 5.89   Max: 43.79
Current: 43.75

5.89
43.79
Revenue Growth (%) 11.50
TMO's Revenue Growth (%) is ranked higher than
84% of the 248 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. TMO: 11.50 )
TMO' s 10-Year Revenue Growth (%) Range
Min: -12.9   Max: 18.7
Current: 11.5

-12.9
18.7
EBITDA Growth (%) 14.30
TMO's EBITDA Growth (%) is ranked higher than
84% of the 210 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.40 vs. TMO: 14.30 )
TMO' s 10-Year EBITDA Growth (%) Range
Min: -30   Max: 40.8
Current: 14.3

-30
40.8
EPS Growth (%) 12.80
TMO's EPS Growth (%) is ranked higher than
82% of the 220 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.90 vs. TMO: 12.80 )
TMO' s 10-Year EPS Growth (%) Range
Min: -41.3   Max: 74.6
Current: 12.8

-41.3
74.6
» TMO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

TMO Guru Trades in Q2 2013

Leon Cooperman 488,670 sh (New)
Andreas Halvorsen 8,689,600 sh (New)
Jeremy Grantham 11,975 sh (New)
John Paulson 5,710,900 sh (New)
Steven Cohen 716,165 sh (+483.95%)
Larry Robbins 8,508,661 sh (+165.78%)
Daniel Loeb 2,500,000 sh (+92.31%)
Pioneer Investments 1,827,637 sh (+6.83%)
Meryl Witmer 5,743,883 sh (+2.7%)
First Pacific Advisors 3,900,300 sh (+0.89%)
Scott Black 138,825 sh (+0.51%)
Steven Romick 3,695,000 sh (unchged)
Jean-Marie Eveillard 200 sh (unchged)
Robert Olstein Sold Out
John Buckingham Sold Out
Arnold Van Den Berg Sold Out
Caxton Associates Sold Out
Louis Moore Bacon Sold Out
Steve Mandel 2,766,476 sh (-2.83%)
Dodge & Cox 100,402 sh (-3.28%)
David Dreman 29,232 sh (-11.07%)
John Rogers 885,018 sh (-17.4%)
John Griffin 4,085,000 sh (-18.46%)
Paul Tudor Jones 3,900 sh (-36.07%)
Brian Rogers 500,000 sh (-88.89%)
» More
Q3 2013

TMO Guru Trades in Q3 2013

Louis Moore Bacon 5,458 sh (New)
Leon Cooperman 615,370 sh (+25.93%)
Andreas Halvorsen 10,570,770 sh (+21.65%)
Pioneer Investments 1,871,730 sh (+2.41%)
First Pacific Advisors 3,906,100 sh (+0.15%)
Jean-Marie Eveillard 200 sh (unchged)
Steven Romick 3,695,000 sh (unchged)
John Paulson 5,710,900 sh (unchged)
Steve Mandel Sold Out
Brian Rogers Sold Out
Paul Tudor Jones Sold Out
Dodge & Cox 99,402 sh (-1%)
David Dreman 28,899 sh (-1.14%)
Larry Robbins 8,083,661 sh (-4.99%)
John Rogers 830,225 sh (-6.19%)
Scott Black 126,266 sh (-9.05%)
John Griffin 3,700,000 sh (-9.42%)
Steven Cohen 638,051 sh (-10.91%)
Daniel Loeb 1,550,000 sh (-38%)
Jeremy Grantham 5,675 sh (-52.61%)
» More
Q4 2013

TMO Guru Trades in Q4 2013

Caxton Associates 23,683 sh (New)
PRIMECAP Management 471,000 sh (New)
Jeremy Grantham 43,565 sh (+667.67%)
Leon Cooperman 825,000 sh (+34.07%)
Larry Robbins 8,535,093 sh (+5.58%)
John Rogers 846,655 sh (+1.98%)
Pioneer Investments 1,900,807 sh (+1.55%)
First Pacific Advisors 3,911,900 sh (+0.15%)
Steven Romick 3,695,000 sh (unchged)
Jean-Marie Eveillard 200 sh (unchged)
Daniel Loeb Sold Out
Dodge & Cox 98,902 sh (-0.5%)
Andreas Halvorsen 10,375,656 sh (-1.85%)
Scott Black 118,570 sh (-6.1%)
John Griffin 3,425,000 sh (-7.43%)
Louis Moore Bacon 4,989 sh (-8.59%)
John Paulson 4,700,000 sh (-17.7%)
David Dreman 14,340 sh (-50.38%)
Steven Cohen 242,053 sh (-62.06%)
» More
Q1 2014

TMO Guru Trades in Q1 2014

Steven Romick 3,315,000 sh (-10.28%)
» More
» Details

Insider Trades

Latest Guru Trades with TMO

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Daniel Loeb 2013-12-31 Sold Out 3.6%$89.93 - $110.67 $ 119.320%0
John Paulson 2013-12-31 Reduce -17.7%0.6%$89.93 - $110.67 $ 119.320%4700000
Leon Cooperman 2013-12-31 Add 34.07%0.33%$89.93 - $110.67 $ 119.320%825000
John Griffin 2013-12-31 Reduce -7.43%0.3%$89.93 - $110.67 $ 119.320%3425000
David Dreman 2013-12-31 Reduce -50.38%0.12%$89.93 - $110.67 $ 119.320%14340
PRIMECAP Management 2013-12-31 New Buy0.06%$89.93 - $110.67 $ 119.320%471000
Daniel Loeb 2013-09-30 Reduce -38%1.82%$84.95 - $94.25 $ 119.332%1550000
Steve Mandel 2013-09-30 Sold Out 1.1%$84.95 - $94.25 $ 119.332%0
John Griffin 2013-09-30 Reduce -9.42%0.4%$84.95 - $94.25 $ 119.332%3700000
Leon Cooperman 2013-09-30 Add 25.93%0.18%$84.95 - $94.25 $ 119.332%615370
Scott Black 2013-09-30 Reduce -9.05%0.13%$84.95 - $94.25 $ 119.332%126266
John Paulson 2013-06-30 New Buy3.4%$75.53 - $88.76 $ 119.343%5710900
Daniel Loeb 2013-06-30 Add 92.31%2.3%$75.53 - $88.76 $ 119.343%2500000
Arnold Van Den Berg 2013-06-30 Sold Out 1.25%$75.53 - $88.76 $ 119.343%0
John Griffin 2013-06-30 Reduce -18.46%0.89%$75.53 - $88.76 $ 119.343%4085000
Leon Cooperman 2013-06-30 New Buy0.63%$75.53 - $88.76 $ 119.343%488670
Daniel Loeb 2013-03-31 New Buy1.9%$63.78 - $77.7 $ 119.364%1300000
Steve Mandel 2013-03-31 New Buy1.1%$63.78 - $77.7 $ 119.364%2847088
Scott Black 2013-03-31 Reduce -8.07%0.11%$63.78 - $77.7 $ 119.364%138122
David Dreman 2013-03-31 Reduce -30.23%0.03%$63.78 - $77.7 $ 119.364%32869
Ray Dalio 2013-03-31 Sold Out 0.03%$63.78 - $77.7 $ 119.364%0
Mario Gabelli 2013-03-31 Sold Out 0.0019%$63.78 - $77.7 $ 119.364%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Thermo Fisher Scientific Inc

Steven Romick's Top Five Highlight Technology Sector
Steven Romick is the portfolio manager of First Pacific Advisors Crescent Fund. The fund’s investment objective and strategy reports that they “seek to generate equity-like returns over the long-term, take less risk than the market and avoid permanent impairment of capital.” Read more...
Weekly Top Insider Sells
According to GuruFocus Insider Data, these are the largest insider sells during the past week. The overall trend of insiders is illustrated in the chart below: Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 34.60
TMO's P/E(ttm) is ranked lower than
51% of the 199 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.10 vs. TMO: 34.60 )
TMO' s 10-Year P/E(ttm) Range
Min: 11.11   Max: 55.16
Current: 34.6

11.11
55.16
P/B 2.50
TMO's P/B is ranked higher than
68% of the 278 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.77 vs. TMO: 2.50 )
TMO' s 10-Year P/B Range
Min: 0.5   Max: 2.72
Current: 2.5

0.5
2.72
P/S 3.30
TMO's P/S is ranked lower than
54% of the 292 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.60 vs. TMO: 3.30 )
TMO' s 10-Year P/S Range
Min: 1.24   Max: 3.54
Current: 3.3

1.24
3.54
PFCF 25.40
TMO's PFCF is ranked higher than
67% of the 164 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.00 vs. TMO: 25.40 )
TMO' s 10-Year PFCF Range
Min: 10.22   Max: 32.28
Current: 25.4

10.22
32.28
EV-to-EBIT 31.30
TMO's EV-to-EBIT is ranked lower than
63% of the 247 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.32 vs. TMO: 31.30 )
TMO' s 10-Year EV-to-EBIT Range
Min: 11.2   Max: 73.5
Current: 31.3

11.2
73.5
PEG 2.30
TMO's PEG is ranked higher than
63% of the 134 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.13 vs. TMO: 2.30 )
TMO' s 10-Year PEG Range
Min: 0.56   Max: 10.09
Current: 2.3

0.56
10.09
Shiller P/E 40.20
TMO's Shiller P/E is ranked lower than
58% of the 127 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 25.28 vs. TMO: 40.20 )
TMO' s 10-Year Shiller P/E Range
Min: 17.09   Max: 75.61
Current: 40.2

17.09
75.61

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.50
TMO's Dividend Yield is ranked lower than
84% of the 155 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.67 vs. TMO: 0.50 )
TMO' s 10-Year Dividend Yield Range
Min: 0.22   Max: 0.86
Current: 0.5

0.22
0.86
Dividend Payout 0.17
TMO's Dividend Payout is ranked higher than
87% of the 140 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.33 vs. TMO: 0.17 )
TMO' s 10-Year Dividend Payout Range
Min: 0.17   Max: 0.17
Current: 0.17

Yield on cost (5-Year) 0.50
TMO's Yield on cost (5-Year) is ranked lower than
78% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.69 vs. TMO: 0.50 )
TMO' s 10-Year Yield on cost (5-Year) Range
Min: 0.22   Max: 0.86
Current: 0.5

0.22
0.86
Share Buyback Rate 3.70
TMO's Share Buyback Rate is ranked higher than
94% of the 218 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.70 vs. TMO: 3.70 )
TMO' s 10-Year Share Buyback Rate Range
Min: 4.6   Max: -38.3
Current: 3.7

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.30
TMO's Price/DCF (Projected) is ranked higher than
78% of the 147 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.40 vs. TMO: 1.30 )
TMO' s 10-Year Price/DCF (Projected) Range
Min: 0.6   Max: 16.04
Current: 1.3

0.6
16.04
Price/Median PS Value 1.60
TMO's Price/Median PS Value is ranked lower than
59% of the 268 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.10 vs. TMO: 1.60 )
TMO' s 10-Year Price/Median PS Value Range
Min: 0.4   Max: 1.45
Current: 1.6

0.4
1.45
Price/Peter Lynch Fair Value 2.60
TMO's Price/Peter Lynch Fair Value is ranked lower than
51% of the 76 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.90 vs. TMO: 2.60 )
TMO' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.62   Max: 2.43
Current: 2.6

0.62
2.43
Earnings Yield (Greenblatt) 3.20
TMO's Earnings Yield (Greenblatt) is ranked lower than
58% of the 226 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.40 vs. TMO: 3.20 )
TMO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.4   Max: 8.9
Current: 3.2

1.4
8.9
Forward Rate of Return (Yacktman) 15.78
TMO's Forward Rate of Return (Yacktman) is ranked higher than
91% of the 217 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. TMO: 15.78 )
TMO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -18.3   Max: 33.3
Current: 15.78

-18.3
33.3

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, COO, ISRG » details
Traded in other countries:TN8.Germany
Thermo Fisher Scientific Inc., is a Delaware corporation and was incorporated in 1956. The Company enables customers to make the world healthier, cleaner and safer by providing analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. In November 2006, Thermo Electron Corporation merged with Fisher Scientific International Inc. to create Thermo Fisher. The Company completed its initial public offering in 1967. It serves more than 350,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental, industrial quality and process control settings. The Company's continuing operations fall into three business segments: Analytical Technologies, Specialty Diagnostics, and Laboratory Products and Services. Analytical Technologies segment provides offerings of instruments, reagents, consumables, software and services that are used for applications in the laboratory, on the production line and in the field. These products are used by customers in all four of the company's key end markets: healthcare and diagnostics; pharmaceutical and biotechnology; academic and government; and industrial and applied. This segment includes four primary businesses - Chromatography and Mass Spectrometry, Chemical Analysis, Environmental and Process Instruments, and Biosciences. Specialty Diagnostics segment provides diagnostic test kits, reagents, culture media, instruments and associated products used to increase the speed and accuracy of diagnoses. Its chemical analysis products fall into three main categories: materials and minerals; molecular spectroscopy; and portable analytical instruments. Customers use these products to quickly and accurately analyze the composition of materials in small samples to optimize workflows in academic, life sciences, pharmaceutical, and industrial applications. These products are used by customers in healthcare, clinical, pharmaceutical, industrial and food safety laboratories. Laboratory Products and Services segment provides virtually everything needed for the laboratory, including a combination of self-manufactured and sourced products and an extensive service offering. These products and services are used by customers in pharmaceutical, biotechnology, academic, government and other research and industrial markets, as well as the clinical laboratory. The Company markets and sells its products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors and various catalogs. It encounters aggressive and able competition in virtually all of the markets it serves. It is subject to various laws and governmental regulations concerning environmental matters and employee safety and health in the United States and other countries.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide